Neimeth Pharmaceuticals commends NAFDAC's reforms, backs local drug manufacturing

Business, Corporate Affairs

LAGOS, Nigeria (NPA) — Neimeth International Pharmaceuticals Plc has commended the National Agency for Food and Drug Administration and Control (NAFDAC) for its ongoing regulatory reforms and renewed efforts to strengthen local pharmaceutical manufacturing in Nigeria.

The commendation came during a courtesy visit by the company’s Board of Directors to NAFDAC’s Lagos office, where members of the delegation met with the agency’s Director-General, Prof. Mojisola Adeyeye.

According to a statement issued by NAFDAC on Sunday, the Neimeth board expressed appreciation for the agency’s initiatives aimed at promoting local drug production, improving regulatory efficiency and supporting pharmaceutical manufacturers to attain international Good Manufacturing Practice (GMP) standards.

The company also reaffirmed its commitment to working closely with NAFDAC to advance the growth and competitiveness of Nigeria’s pharmaceutical industry.

Receiving the delegation, Prof. Adeyeye thanked the board for the visit and reiterated the agency’s commitment to building a globally competitive pharmaceutical sector through transparent, science-based regulation and sustained collaboration with industry stakeholders.

She said NAFDAC would continue implementing reforms designed to strengthen Nigeria’s regulatory framework and improve international confidence in locally manufactured medicines.

The Director-General highlighted the agency’s ongoing efforts to secure membership of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and its continued progress towards attaining higher levels under the World Health Organization’s Global Benchmarking Tool.

According to her, the initiatives are expected to enhance the quality and global acceptance of Nigerian pharmaceutical products while expanding export opportunities for local manufacturers.

The meeting concluded with both NAFDAC and Neimeth reaffirming their shared commitment to strengthening local pharmaceutical manufacturing, improving the quality of medicines and ensuring a sustainable supply of safe, effective and quality-assured medicines for Nigerians.

Both parties also pledged to sustain collaboration in promoting regulatory excellence, supporting industry growth and enhancing Nigeria’s competitiveness in the global pharmaceutical market.